Association study of lipoprotein(a) genetic markers, traditional risk factors, and coronary heart disease in HIV-1-infected patients. by Egaña Gorroño, Lander et al.
“ﬁmmu-03-00367” — 2012/12/5 — 20:24 — page 1 — #1
ORIGINAL RESEARCH ARTICLE
published: 06 December 2012
doi: 10.3389/ﬁmmu.2012.00367
Association study of lipoprotein(a) genetic markers,
traditional risk factors, and coronary heart disease
in HIV-1-infected patients
Lander Egaña-Gorroño1, Esteban Martínez2,Tuixent Escribà1, Marta Calvo2,
José M. Gatell1,2 and Mireia Arnedo1*
1 Group of Genomics and Pharmacogenomics in HIV, Retrovirology and Viral Immunopathology Laboratory, Institut D’Investigacions
Biomèdiques August Pi i Sunyer, Hospital Clínic Barcelona, Barcelona, Spain
2 Department of Infectious Diseases, Hospital Clínic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
Edited by:
Guido Poli, Vita-Salute San Raffaele
University, Italy
Reviewed by:
Angelo A. Manfredi, Vita-Salute San
Raffaele University, Italy
GiuseppeTambussi, Istituto di
Ricovero e Cura a Carattere Scientiﬁco
Ospedale San Raffaele, Italy
*Correspondence:
Mireia Arnedo, Group of Genomics
and Pharmacogenomics in HIV,
Retrovirology and Viral
Immunopathology Laboratory,
Institut D’Investigacions Biomèdiques
August Pi i Sunyer, Hospital Clínic
Barcelona, Casanovas 143,
Barcelona 08036, Spain.
e-mail: marnedo@clinic.ub.es
Objectives: General population studies have shown associations between copy number
variation (CNV) of the LPA gene Kringle-IV type-2 (KIV-2) coding region, single-nucleotide
polymorphism (SNP) rs6415084 in LPA and coronary heart disease (CHD). Because risk
factors for HIV-infected patients may differ from the general population, we aimed to
assess whether these potential associations also occur in HIV-infected patients. Methods:
A unicenter, retrospective, case–control (1:3) study. Eighteen HIV-patients with conﬁrmed
diagnosis of acute myocardial infarction (AMI) were adjusted for age, gender, and time
since HIV diagnosis to 54 HIV-patients without CHD. After gDNA extraction from frozen
blood, both CNV and SNP genotyping were performed using real-time quantitative PCR.
All genetic and non-genetic variables for AMI were assessed in a logistic regression anal-
ysis. Results: Our results did not conﬁrm any association in terms of lipoprotein(a) LPA
structural genetic variants when comparing KIV-2 CNV (p = 0.67) and SNP genotypes
(p = 0.44) between AMI cases and controls. However, traditional risk factors such as dia-
betes mellitus, hypertension, and CD4+ T cell count showed association (p < 0.05) with
CHD. Conclusion: Although signiﬁcant associations of AMI with diabetes, hypertension
and CD4+ T cell count in HIV-patients were found, this study could not conﬁrm the feasibil-
ity neither of KIV-2 CNV nor rs6415084 in LPA as genetic markers of CHD in HIV-infected
patients.
Highlights:
• Individuals with HIV infection are at higher risk of coronary heart disease (CHD) than the
non-infected population.
• Our results showed no evidence of LPA structural genetic variants associated with CHD
in HIV-1-infected patients.
• Associations were found between diabetes mellitus, arterial hypertension, CD4+ T cell
count, and CHD.
• The clinical usefulness of these biomarkers to predict CHD in HIV-1-infected population
remains unproven.
• Further studies are needed to assess the contribution of common genetic variations to
CHD in HIV-infected individuals.
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INTRODUCTION
Since the ﬁrst case reports of acute myocardial infarction (AMI)
in HIV-1-infected patients on highly active antiretroviral ther-
apy (HAART) were described, it has become increasingly evident
that individuals with HIV infection are at higher risk of cardio-
vascular events than the general population (Triant et al., 2007).
Besides, the contribution of classic risk factors, other factors
such as viral replication, HIV-associated inﬂammation and/or
immunodeﬁciency, and antiretroviral therapy have been associ-
ated with premature cardiovascular disease (CVD; Friis-Møller
et al., 2003; Hansson, 2005). The study of genetic traits and
their relation to complex diseases, e.g., CVD, still poses a major
challenge.
Increased plasma concentrations of atherogenic lipoproteins
play an important role in the development of atherosclerosis
leading to premature AMI and ischemic stroke. One particular
fraction, which is important in that respect, is lipoprotein(a)
[Lp(a)]. Elevated plasma concentrations of Lp(a) have been
associated with the risk of coronary heart disease (CHD) in
the general population (Rhoads et al., 1986; Ridker et al., 1993;
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Ohira et al., 2006). The plasma concentration of Lp(a) varies
over a wide range among individuals. Furthermore, the inter-
individual variation in Lp(a) level is 90% genetically determined
by the LPA locus on chromosome 6, although plasma Lp(a) in a
particular individual remains stable over a lifetime (Boerwinkle
et al., 1992).
Lipoprotein(a) is composed of an apolipoprotein(a) [Apo(a)]
molecule encoded by LPA, which is connected via a disulphide
bond to the apolipoprotein B-100 of a proatherogenic LDL-
cholesterol particle (McLean et al., 1987; Berglund and Rama-
krishnan, 2004). The Apo(a) molecule is composed of a signal
peptide region, 10 types of kringles that differ in sequence but
are homologous to plasminogen kringle IV (KIV1–10), a kringle
homologous to plasminogen kringle V (KV) and an inactive
protease-like domain (McLean et al., 1987; Gavish et al., 1989).
The size of Apo(a) is determined by a copy number variation
(CNV) of the kringle-IV type 2 (KIV-2) coding region (encoded
by exons 4 and 5 in LPA gene), and this being negatively cor-
related with Lp(a) levels (Lanktree et al., 2009). The genetically
determined KIV-2 repeat number affects the ﬁnal size of the
Apo(a) protein, with larger isoforms being compromised with
respect to protein folding, transport, and secretion (Lanktree
et al., 2010). Furthermore, the LPA single-nucleotide polymor-
phism (SNP) rs6415084 (C → T), within the same haplotype
block as the KIV-2 CNV, has been reported to be signiﬁcantly
associated with both Lp(a) concentrations and the KIV-2 copy
number (CN; Paultre et al., 2000; Clarke et al., 2009). Several stud-
ies have identiﬁed increased atherogenesis andCHD in individuals
with fewer apo(a) KIV-2 repeats (Kraft et al., 1992, 1996; Sand-
holzer et al., 1992). The number of KIV-2 repeats varies among
subjects and ranges from 11 to >50 (Kannel et al., 1976; Lack-
ner et al., 1993). Contrary to KIV-2 with CN > 25, a CN ≤ 22
leads to signiﬁcantly higher Lp(a) levels, which are more fre-
quent in CHD patients (Sandholzer et al., 1992; Kraft et al., 1996).
The aim of this study was to test whatever association between
KIV-2 CNV and CHD could be conﬁrmed in HIV-infected
patients, as well as association between classical clinical risk factors
and CHD.
MATERIALS AND METHODS
The study population consisted of 72 HIV-1-infected individuals
under HAART who were followed-up at the Hospital Clínic of
Barcelona during the study period (January 1, 1997 to Decem-
ber 31, 2008). They had all signed the ethical informed consent
for genetic testing. The retrospective case–control study (1:3) was
based on CHD patients from whom genetic testing could be per-
formed (n = 18). CHD was deﬁned according to the criteria of the
Joint European Society of Cardiology and theAmerican College of
Cardiology Committee for the Redeﬁnition of Myocardial Infarc-
tion (The Joint European Society of Cardiology/American College
of Cardiology Committee, 2000). Patients with CHD, had either
an ST-segment elevation myocardial infarction (n = 11, 61%) or a
non-ST-segment elevation myocardial infarction (n = 7, 39%) if
there was or not an evolving ST-segment elevation>0.1mV in two
contiguous leads, respectively. Each case was matched by age, gen-
der, and time since HIV diagnosis to three controls without CHD
(n = 54). Besides age and gender, relevant data on HIV infection
and on clinical risk factors for CVD were collected. DNA was
isolated from frozen blood according to manufacturer’s instruc-
tions using the QIAamp DNA Blood Mini Kit, automated by
QIAcube (QIAGEN). For the CNV analysis a multiplex qPCR was
carried out using custom TaqMan probes for exons 4 and 5 in LPA
and single-copy reference gene RNaseP (part number 4316844)
in the Applied Biosystems 7900HT Fast Real-time PCR System.
Reaction volumes contained 4 μl of water, 1 μl of 20× TaqMan
primer/probe mix for LPA, 1 μl of 20× TaqMan primer/probe
mix for RNaseP, 10 μl of 2× Genotyping Master Mix (Applied
Biosystems), and 4 μl of genomic DNA at a ﬁnal concentration
of 5–10 ng. Six replicates were run in all qPCRs. Thermocycler
conditions were as follows: 95◦C hot-start for 10 min, followed by
40 cycles at 95◦C for 15 s and 60◦C for 1 min. Absolute quantiﬁ-
cation (AQ) ﬁles were then exported to the Copy Caller Software
(Applied Biosystems) for relative quantiﬁcations (RQ) and ﬁnal
CN analysis.
Intronic SNP rs6415084 in LPA genewas genotyped by TaqMan
Allelic Discrimination, using TaqMan SNP genotyping assays pre-
designed by Applied Biosystems (part number C_27422575_10).
Reaction volumes contained 1.25 μl of 20× TaqMan SNP Assay,
12.5 μl of 2× Universal Master Mix (Applied Biosystems), and
11.25μl of genomicDNAat aﬁnal concentrationof 1–20ng. Ther-
mocycler conditions were as follows: 95◦C hot-start for 10 min,
followed by 40 cycles at 95◦C for 15 s and 60◦C for 1 min.
15% of the total samples were re-genotyped in order to check
reproducibility.
A basic case/control association test, based on a Fisher’s exact
test, was performed by comparison of calculated CN variants
and SNP genotypes between AMI cases and controls using SNPa-
tor software (CEGEN, Barcelona, Spain). A multivariate analysis
through logistic regression model was performed in order to assess
the inﬂuence of genetic and non-genetic variables using SPSS v.15.
With the sample size available, any difference above 20% would
have been detected with a power of 80%.
RESULTS
Baseline characteristics of the study participants are shown in
Table 1. The median age was 44 years (interquartile range 12).
Men represented 88.9% in both groups. Groups of risk for HIV
acquisition were 50% homosexuals, 25% heterosexuals, and 25%
injection drugs users in both groups. The median CD4+ T cell
count (cell/μl) was 107 (interquartile range 261) in the cases and
210 (interquartile range 275) in the controls. HIV viral load (log)
was 4.81 (interquartile range 5.92) in the cases and 4.62 (interquar-
tile range 5.34) in the controls. A total of 88.9% of cases and 64.8%
of controls were exposed to protease inhibitor containing regi-
mens. Diabetes mellitus and usual smokers were present in 22.2
and 55.5% of cases and 14.8 and 37.03% of controls, respectively.
A total of 22.2% of cases and 9.25% of controls had hypertension,
and 22.2% of cases and 3.7% of controls had family antecedents
of CVD. At least, one AIDS event was suffered by 2 (11.1%) cases
and 12 (22.2%) controls. Both groups had a median Framingham
risk score (FRS) of 2% (interquartile range 14 in cases and 5.5 in
controls).
All participantswere successfully genotyped. As it was expected,
the LPA KIV-2 repeat analysis ranged between 17 and 48 copies.
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Table 1 | Baseline characteristics of the study participants.
Characteristic Study participants (n = 72)
AMI (n = 18) NoAMI (n = 54)
Age, years* 44 (12) 42 (12)
Men/women, n (% men) 16 (88.9) 48 (88.9)
Ethnicity, n (%)
Caucasian 16 (88.9) 52 (96.3)
Unknown/other 2 (11.1) 2 (3.7)
Presumed mode of HIV transmission, n (%)
Men who have sex with men 9 (50) 26 (48.1)
Heterosexual 4 (22.2) 14 (25.9)
Injection drug user 5 (27.8) 10 (18.5)
Other/unknown 0 (0) 4 (7.4)
Follow-up period
At HIV diagnostic time:
CD4+ T cell count (cell/μl)* 107 (261) 210 (275)
HIV Viral load (log)* 4.81 (5.92) 4.62 (5.34)
At time of event:
CD4+ T cell count (cell/μl)* 573.5 (377) -
HIV Viral load (log)* 2.99 (3.96) -
Exposure to PI, n (%) 16 (88.9) 35 (64.8)
Exposure to other HAART
regimens, n (%)
2 (11.1) 19 (35.2)
Smokers, n (%) 10 (55.5) 20 (37.03)
Diabetes mellitus, n (%) 4 (22.2) 8 (14.8)
Hypertension, n (%) 4 (22.2) 5 (9.25)
Familial antecedents, n (%) 4 (22.2) 2 (3.7)
AIDS events, n (%) 2(11.1) 12 (22.2)
Framingham risk score (%)* 2 (14) 2 (5.5)
AMI, acute myocardial infarction; PI, protease inhibitor; HAART, highly active
antiretroviral therapy. *Median (interquartile range).
The case/control analysis showed CN ≤ 22 in seven patients (one
case vs. six controls) and CN > 25 in 65 patients [17 cases vs.
48 controls; p = 0.46; OR = 0.44 (0.049–3.99)]. SNP rs6415084
was checked to conﬁrm Hardy–Weinberg equilibrium. Genotyp-
ing assay showed common homozygosity (C/C) in 17 patients (3
cases vs. 14 controls), rare homozygosity (T/T) in 20 patients (7
cases vs. 13 controls), and heterozygosity (C/T) in 35 patients
[8 cases vs. 27 controls; p = 0.42; OR = 0.57 (0.144, 2.274)].
Logistic regression analysis showed signiﬁcant associations
(p < 0.05) between traditional risk factors such as diabetes mel-
litus, hypertension, and CD4+ T cell count at HIV-infected
diagnosis and CHD (Table 2). The strength of the association was
quantiﬁed using the odds ratios and the 95% conﬁdence intervals.
CONCLUSION
The most important ﬁnding in our study is that we were able to
detect associations between clinical risk factors and CHD. Non-
genetic variables such us diabetes mellitus, hypertension, and
Table 2 | Multivariate analysis through logistic regression including all
genetic and non-genetic co-variables.
Co-variable p-Value OR 95% CI
Lower Upper
Exposure to PI 0.906 8.68 0.46 12.87
Smoker 0.277 2.044 0.563 7.424
Diabetes mellitus 0.024* 2.44 2.3 5.78
Hypertension 0.035* 3.576 2.52 3.96
Familial antecedents 0.74 6.912 0.829 5.764
AIDS events 0.569 0.603 0.105 3.449
Viral load (log) 0.368 1.204 0.152 1.965
CD4+ T cell count (cell/μl) 0.042* 1.22 1.06 1.047
Genetic variables:
rs6415084 0.528 0.594 0.118 2.987
KIV-2 CNV 0.776 1.015 0.914 1.128
PI, protease inhibitor; CNV, copy number variation; OR, odd ratio; 95% CI, 95%
conﬁdence interval; *p < 0.05.
CD4+ T cell count at HIV-infected diagnosis reached signiﬁcance
in the logistic regression analysis. The inﬂuence of CD4+ T cell
level on CVD is supported by previously reported studies (Paultre
et al., 2000). However, any previously described associations
between LPA genetics biomarkers (KIV-2 CNV nor rs6415084)
and CHD were found. The association between SNPs in LPA gene
and circulating Lp(a) levels, and consequently with CHD, may
be mediated by various mechanisms: (i) some of the SNPs may
be in linkage disequilibrium with the KIV-2 repeat polymorphism
which has been shown to explain approximately 50%of the genetic
variation in Lp(a) concentrations; (ii) certain SNPs may directly
inﬂuence the transcriptional and/or translational processes of the
LPA gene (Paultre et al., 2000); and (iii) some non-causal SNPs
may be in linkage disequilibrium with SNPs having causal effect
on Lp(a) concentrations. The main important limitation of our
study was the low absolute number of HIV-patients with doc-
umented AMI. Furthermore, larger number of individuals could
not be included in the study because of the unavailability of data or
blood sample for the purpose of this study. Lp(a) concentrations
from frozen blood could not be measured. Although the power of
the study was limited due to the small sample size analyzed, there
is no other study regarding CNV in LPA and CHD in HIV-infected
patients.
In summary, our results did not conﬁrm evidence of LPA struc-
tural genetic variants associated with CHD in HIV-1-infected
patients. Although the power of the study was limited, tradi-
tional risk factors are contributing to the progression of CHD
amongst HIV-infected population as well as they do in non-HIV
population. Moreover, there are factors in HIV-infected popula-
tion that are not present in non-HIV-infected individuals and are
unrelated to genetics: HIV and HAART. The pathogenesis of HIV-
1-infection and/or exposure to HAART might contribute to CHD
in a stronger way than LPA genetic variants do. The clinical utility
of these biomarkers to predict CHD in HIV-1-infected population
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therefore remains unproven. Further collaborative studies with a
larger number of HIV-infected patients are needed.
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